Werewolf Therapeutics, Inc.

As of August 14, 2025, Werewolf Therapeutics, Inc. is considered overvalued with a valuation grade of "does not qualify," highlighted by a Price to Book Value of 1.11, a low EV to Capital Employed of 0.05, and a negative ROE of -127.93%, while significantly underperforming its peers and the S&P 500.

As of August 11, 2022, Werewolf Therapeutics, Inc. is considered overvalued and risky, with a negative P/E ratio of -0.7406, significantly underperforming the S&P 500 by -56.6% over the past year, compared to its peers.

As of June 20, 2025, the market trend is mildly bearish, influenced by daily moving averages and monthly Bollinger Bands, despite some mildly bullish indicators on the weekly MACD and KST.

Werewolf Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $18 million and a market cap of $54.30 million. Key metrics include a negative P/E ratio, no dividend yield, and a return on equity of -127.93%.

As of Jun 18, Werewolf Therapeutics, Inc. has a market capitalization of 54.30 million, with net sales of 1.14 million and a net profit of -72.41 million over the latest four quarters. Shareholder's funds are at 73.39 million, and total assets amount to 129.50 million.